Tice R R, Strauss G H, Peters W P
Integrated Laboratory Systems, Research Triangle Park, NC 27709.
Mutat Res. 1992 Apr;271(2):101-13. doi: 10.1016/0165-1161(92)91083-4.
The single cell gel (SCG) assay is a sensitive electrophoretic technique for detecting the presence of DNA single strand breaks and alkali-labile damage in individual cells. This technique was used to evaluate the levels of DNA damage in cryopreserved peripheral blood lymphocytes (PBLs) from 11 breast cancer patients treated with high doses of cyclophosphamide and cisplatin and provided autologous bone marrow transplantation after treatment. PBL specimens for the SCG study were obtained just prior to treatment, following the administration of cyclophosphamide and cisplatin for 2 days, and upon lymphocytic recovery. Based on a concurrent analysis of DNA damage in cryopreserved and non-cryopreserved PBL samples from three patients, the mean level of DNA migration or the dispersion of damage among cells was not affected by the process of cryopreservation. The pre-treatment samples of several patients contained PBL with increased levels of DNA damage, presumably reflecting persistent DNA damage induced by previous treatment regimens. Chemotherapy resulted in a significant but variable increase in DNA damage in PBL samples from all patients. In this limited study, the level of damage did not correlate with serum levels of cyclophosphamide or with lymphocyte toxicity. Among the post-treatment samples, increased levels of DNA damage were absent in most but not all patients. The presence of damaged cells in the post-treatment samples may be indicative of an inadequate therapy regimen or of DNA damage resulting from non-therapy related processes. Because of its simplicity and short processing time, the SCG assay can be used to evaluate levels of DNA damage during the course of therapy, allowing the dose schedule to be altered to achieve a desired effect level.
单细胞凝胶（SCG）试验是一种灵敏的电泳技术，用于检测单个细胞中DNA单链断裂和碱不稳定损伤的存在。该技术用于评估11例接受高剂量环磷酰胺和顺铂治疗并在治疗后进行自体骨髓移植的乳腺癌患者冷冻保存的外周血淋巴细胞（PBL）中的DNA损伤水平。用于SCG研究的PBL标本在治疗前、环磷酰胺和顺铂给药2天后以及淋巴细胞恢复时获取。基于对三名患者冷冻保存和未冷冻保存的PBL样本中DNA损伤的同步分析，DNA迁移的平均水平或细胞间损伤的分散程度不受冷冻保存过程的影响。几名患者的治疗前样本中PBL的DNA损伤水平升高，可能反映了先前治疗方案引起的持续性DNA损伤。化疗导致所有患者PBL样本中的DNA损伤显著但有差异地增加。在这项有限的研究中，损伤水平与环磷酰胺的血清水平或淋巴细胞毒性无关。在治疗后样本中，大多数但并非所有患者的DNA损伤水平没有升高。治疗后样本中存在受损细胞可能表明治疗方案不足或非治疗相关过程导致的DNA损伤。由于其简单性和较短的处理时间，SCG试验可用于评估治疗过程中的DNA损伤水平，从而调整剂量方案以达到所需的效应水平。
